Indegene has been named a Leader in the ISG Provider Lens™ for Life Sciences Digital Services in Commercial Operations for 2026. This marks the third consecutive year the company has received this industry recognition. The assessment highlights Indegene’s success in leveraging its NEXT Technology Platform and Cortex, along with advanced AI and GenAI capabilities, to drive data-led, integrated commercial models for global biopharma and medical technology organizations.
Advancing Digital Transformation in Life Sciences
Indegene continues to demonstrate its expertise in orchestrating complex commercial, medical, and R&D operations. By focusing on AI-native solutions, the company enables life sciences enterprises to transition from fragmented digital initiatives toward highly orchestrated, intelligence-led execution. This approach is designed to modernize the entire commercial value chain, from initial planning to final execution.
Proprietary Technology Platforms
At the core of Indegene’s success are its proprietary assets, NEXT Technology Platform and Cortex. These platforms facilitate structured content management and workflow automation, providing clients with the tools necessary for targeted healthcare professional (HCP) engagement. By converting data into actionable insights, these solutions help improve operational efficiency and ensure consistent, measurable business outcomes.
Strategic Commitment to AI-Native Operations
As the life sciences industry accelerates toward fully connected ecosystems, Indegene is focused on helping clients operationalize data for real-world impact. According to company leadership, the future of commercial operations lies in intelligence-led models that offer speed, precision, and consistency. This third-year recognition from ISG reinforces Indegene’s position as a trusted strategic partner for the world’s top 20 biopharma companies.
Source: BSE
